AVM Biotechnology

AVM's biotechnology 'software' will make the 'hardware' of stem cells work optimally : non-invasive delivery and fully human biologics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, USA
  • Currency USD
  • Founded January 2008
  • Employees 5
  • Website avmbiotech.com

Company Summary

AVM’s unique technology and mission present a clear advantage over the current technologies that rely on aborted fetal material. i) Biologic based manipulation of stem cell distribution to enhance organ repair, ii) Boutique Biologic manufacturing using patient specific stem cells for chronic diseases such as hemophilia. Out-licensing strategy reduces risk of typical biotech and presents near term capital return.

Team

  • Theresa A Deisher
    President & CEO

    PhD in Cellular and Molecular Physiology from Stanford University (1990) ; Over 19 years in commercial biotech with Genentech, Repligen, ZymoGenetics, Immunex and Amgen, prior to founding AVM. Inventor on 23 issued US patents; Discoveries have led to clinical trials of FGF18 for osteoarthritis and cartilage repair, and for Factor XIII for surgical bleeding. Over $100M revenue from patents. First person to discover adult cardiac derived stem c

  • Mike Kuran
    EVP

    20 years experience in big pharma, biotech and startup companies;
    ZymoGenetics (Seattle, WA), and Novo Nordisk and IMS Health (Tokyo, Japan); Deal sheet includes Takeda, Novo Nordisk, J&J, Merck Serono, Mitsubishi Tanabe, Meiji Seika, Ciba-Geigy, Bayer, Novartis, Eisai, Colgate-Palmolive, Sunstar, Ajinomoto, PPL, Fibrogen, BMS, Eli Lilly, Amgen, Immunex, Kirin;
    Founder, Artemisia BioMedical, (Seattle, WA)

  • Theresa Deisher

Advisors

  • Foster Pepper LLC
    Lawyer
    Unconfirmed
    Greenwood Olhund LLC
    Accountant
    Unconfirmed

Previous Investors

  • Series A in progress
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free